The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy

Frontiers in Immunology

Immunology

Quanhong Jiang¹  Xiangbo Meng¹  Mingxia Liu²  Junmin Wei³  Rui Chen³ 

[1] Advanced Medical Research Institute, Meili Lake Translational Research Park, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China;Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China;Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China;

关键词: cGAS-STING;    tumor;    immune regulation;    immunotherapy;    clinical application;   

DOI  :  10.3389/fimmu.2023.1121603

 received in 2022-12-12, accepted in 2023-04-07,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) synthase (cGAS) detects infections or tissue damage by binding to microbial or self-DNA in the cytoplasm. Upon binding DNA, cGAS produces cGAMP that binds to and activates the adaptor protein stimulator of interferon genes (STING), which then activates the kinases IKK and TBK1 to induce the secretion of interferons and other cytokines. Recently, a series of studies demonstrated that the cGAS-STING pathway, a vital component of host innate immunity, might play an important role in anticancer immunity, though its mechanism remains to be elucidated. In this review, we highlight the latest understanding of the cGAS-STING pathway in tumor development and the advances in combination therapy of STING agonists and immunotherapy.

【 授权许可】

Unknown   
Copyright © 2023 Chen, Liu, Jiang, Meng and Wei